Monoclonal antibody dose determination and biodistribution into solid tumors

Therapeutic Delivery

Volumn 2, Issue 3, 2011, Pages 333-344

  Beckman, Robert A ^a   Von Roemeling, Reinhard ^a   Scott, Andrew M ^b,c  

^a DAIICHI SANKYO INC   (United States)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; IODINE 131; MONOCLONAL ANTIBODY; PANITUMUMAB; PLACEBO; RITUXIMAB; TRASTUZUMAB;

ANAPHYLAXIS; AREA UNDER THE CURVE; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; DRUG TUMOR LEVEL; DRUG UPTAKE; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

EID: 79952679436     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.91     Document Type: Review

References (44)

1. Ehrlich P. On immunity with specifc reference to cell life. Proc. R. Soc. Lond. 66, 429 (1900).
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefned specifcity. Nature 256, 495-497 (1975).
3. Chang JT, Carvalho C, Mori S et al. A genomic strategy to elucidate pathways of oncogenic signaling networks. Mol. Cell 34, 104-114 (2009).
4. Herlyn DM, Koprowski H. Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity Int. J. Cancer 27, 769-774 (1981). (Pubitemid 11125613)
5. Barriere J, Fischel J, Formento P et al. Cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) against tumor cell lines characterized for EGFR expression and K-ras mutation. J. Clin. Oncol. 27(Suppl.), (2009) (Abstract e14583).
6. Thorpe PE, Ross WCJ. The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol. Rev. 62, 119-158 (1982). (Pubitemid 12107819)
7. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol. 13, 235-244 (2009).
8. Pohlman B, Sweetenham J, Macklis RM. Review of clinical radioimmunotherapy Expert Rev. Anticancer Ther. 6, 445-461 (2006). (Pubitemid 44192926)
9. Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J. 14, 178-183 (2008).
10. Chen S, Yu L, Jiang C et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol. 23, 1538-1547 (2005).
11. Yan L, Ehrlich PJ, Gibson R, Pickett C, Beckman RA. How can we improve antibody-based cancer therapy? Monoclonal Antibodies 1, 67-70 (2009).
12. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170-179 (2007). (Pubitemid 46106231)
13. Gibson CR, Sandhu P, Hanley WD. Monoclonal antibody pharmacokinetics and pharmacodynamics. In: Therapeutic Monoclonal Antibodies: from Bench to Clinic. An Z (Ed.). John Wilet & Sons, Inc., Hoboken, NJ, USA 439-460 (2009).
14. Sedlacek HH, Seemann G, Hoffmann D et al. Antibodies as Carriers of Cytotoxicity. Karger, Basel, Switzerland (1992).
15. Jain RK. Physical barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50, 814s-819s (1990).
16. Gutmann R, Leunig M, Feyh J et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 52, 1993-1995 (1991).
17. Nugent LJ, Jain RK. Extravascular diffusion in normal and neoplastic tissues. Cancer Res. 144, 238-244 (1984). (Pubitemid 14177745)
18. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31, 288-308 (1986).
19. Clauss MA, Jain RK. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res. 50, 3487-3492 (1990). (Pubitemid 20194084)
20. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60, 2497-2503 (2000). (Pubitemid 30262444)
21. Clauss MA, Jain RK. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res. 50, 3487-3492 (1990). (Pubitemid 20194084)
22. Melkko S, Halin C, Borsi L, Zardi L, Neri D. An antibody calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor-targeting performance. Int. J. Radiat. Oncol. Biol. Phys. 54, 1485-1490 (2002). (Pubitemid 35380053)
23. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling ana lysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med. 31, 1191-1198 (1990). (Pubitemid 20213280)
24. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol. Sci. 29, 57-61 (2008).
25. Thurber GM, Wittrup KD. Quantitative spatiotemporal ana lysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res. 68, 3334-3341 (2008).
26. Graff CP, Wittrup KD. Theoretical ana lysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affnity for retention. Cancer Res. 63, 1288-1296 (2003). (Pubitemid 36348707)
27. Schmidt MM, Wittrup KD. A modeling ana lysis of the effects of molecular size and binding affnity on tumor targeting. Mol. Cancer. Ther. 8, 2861-2871 (2009).
28. Adams GP, Schier R, McCall AM et al. High affnity restricts the localization and tumor penetration of single chain Fv antibody molecules. Cancer Res. 61, 4750-4755.
29. Verel I, Heider KH, Siegmund M et al. Tumor targeting of antibodies with different affnity for target antigen CD44V6 in nude mice bearing head and neck cancer xenografts. Int. J. Cancer. 99, 396-402 (2002). (Pubitemid 34495853)
30. Blumenthal RD. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol. Immunother. 33, 351 (1991).
31. Wittrup KD. Tumor-targeting theory-kinetic and diffusive processes that determine antibody macro and microdistribution. Presented at: The Biorbis Antibody Engineering and Design Conference. Boston, MA, USA, 28-29 July 2010.
32. Scott AM, Lee FT, Jones R et al. Phase I biopsy-based study of humanized monoclonal antibody A33 in patients with colorectal carcinoma. Clin. Cancer Res. 11, 4810-4817 (2005).
33. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies, scale up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 55, 4611-4622 (1995).
34. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J. Natl Cancer Inst. 96, 990-997 (2004). (Pubitemid 39162641)
35. Shak S. For the Herceptin Multinational Investigator Study Group. Overview of the trastuzumab (Herceptin®) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin. Oncol. 26(Suppl. 12), 71-77 (1999). (Pubitemid 29411435)
36. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457-2466 (1994). (Pubitemid 24317376)
37. Lockhart AC, Braun RD, Yu D et al. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res. 9, 586-593 (2003). (Pubitemid 36182588)
38. Maheswaren S, Sequist L, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. New Engl. J. Med. 359, 366-377 (2008).
39. Herbertson RA, Tebbutt NC, Lee F-T et al. Phase I biodistribution of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin. Cancer Res. 15, 6709-6715 (2009).
40. Joshi A, Bauer R, Kuebler P. et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J. Clin. Pharmacol. 46, 10-20 (2006). (Pubitemid 43021710)
41. Orlova A, Tolmachev V, Pehrson R et al. Synthetic affbody molecules: a novel class of affnity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 67, 2178-2186 (2007). (Pubitemid 46424237)
42. Stumpp MT, Amstutz P. DARPins: a true alternative to antibodies. Curr. Opin. Drug Discov. Devel. 10, 153-159 (2007). (Pubitemid 46438644)
43. Kelly MP, Lee FT, Tahtis K et al. Tumor targeting by multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother. Radiopharm. 23, 411-423 (2008).
44. Chen C, Beckman RA. Optimal cost-effective Go-No-Go decisions in late stage oncology drug development. Stat. Biopharm. Res. 1, 159-169 (2009).